Home › NCT06340685
Triheptanoin for Children With Primary-Specific Pyruvate Dehydrogenase Complex (PDC) Deficiency
An Open Label, Exploratory, Proof-of Concept Study of Triheptanoin as Treatment for Patients With Primary-Specific Pyruvate Dehydrogenase Complex (PDC) Deficiency
Who can join
Ages 1 to 17 · All sexes
Full eligibility criteria
Inclusion Criteria: 1. Age 1 year to \<18 years of age 2. Subjects with PDCD would need to have a metabolic physician following their clinical care needs prior to their enrollment in the study 3. Diagnosis of PDCD by molecular genetic confirmation of PDHA1, PDHB, DLAT, PDHX, or PDP1 mutation 4. Not pregnant or lactating 5. Parental permission and assent of minor and willingness to comply with study procedures 6. Not participating in any interventional treatment clinical trials 7. Not a recipient of gene therapy, organ transplant, or bone-marrow transplantation 8. If currently on any investigational drugs or therapies, must complete a 30-day washout period prior to Intake \& Dosing (Day 1). 9. Negative pregnancy test for all female patients of childbearing age. Individuals of childbearing potential must agree to use a highly effective method of contraception, and males must agree not to father a child or donate sperm. True abstinence for the duration of the study will also be accepted. 10. Subjects are following some form or type of ketogenic diet at the time of the screening visit. Exclusion Criteria: 1. Diagnosis of medium-chain acyl-CoA dehydrogenase (MCAD) 2. Use of alcohol or drugs of abuse 3. Evidence of liver disease as defined by elevations of AST or ALT \>2x ULN in the past 6 months 4. Pregnant, breastfeeding, or lactating females 5. On any investigational product research study (and not completed the required 30-day washout period prior to Intake \& Dosing) or recipient of gene therapy or organ or bone-marrow transplantation
About the study
This is a medical research study to test a medication in patients with a disease called Pyruvate Dehydrogenase Complex (PDC) Deficiency. The medication is triheptanoin, which is currently FDA approved for the treatment of Long-Chain Fatty Acid Oxidation Disorders. Previous research suggests that triheptanoin may also be effective in the treatment PDC Deficiency. This study will investigate the safety and efficacy (how well it works) of triheptanoin in patients with PDC Deficiency.
What is being tested
- Triheptanoin (drug)
Sponsor: Jirair Krikor Bedoyan · Participants: 6 · Started: Jul 11, 2024
Contact the study team
- Angela Riemenschneider · Phone: 412-692-5232
Official record on ClinicalTrials.gov — NCT06340685
Locations in the U.S.
| Pennsylvania | UPMC Children's Hospital of Pittsburgh, Pittsburgh |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.